TORONTO, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Beleave Inc. ("Beleave" or the "Company") (CSE:BE) (OTCQX:BLEVF) is pleased to announce that effective immediately its common shares have been approved for trading on OTCQX®, the highest tier of the OTC market, exclusively for US and international companies that undergo a rigorous financial and qualitative review. The Company's common shares will trade under the ticker "BLEVF".
Joining OTCQX coincides with the Company's ongoing efforts to support its existing U.S. shareholder base. U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.
“We are pleased to be able to provide our current and potential U.S. investors an improved platform to access our company’s securities,” commented Roger Ferriera, Beleave’s CEO. “We welcome the opportunity to add to our growing investor base in the United States.”
The OTCQX® Market is for established investor-focused U.S. and global companies. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, demonstrate compliance with U.S. securities laws, and have a professional third-party sponsor introduction.
Beleave will continue to trade on the Canadian Stock Exchange under its existing symbol "BE".
About Beleave
Beleave Inc. is a biotech company and Beleave's wholly-owned subsidiary Beleave Kannabis Corp. (formerly First Access Medical Inc.) is a licensed producer pursuant to the ACMPR. Beleave's purpose-built facility is located near Hamilton, Ontario.
Forward-Looking Statements
This news release contains forward-looking information. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking information. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. These risks and uncertainties include, but are not limited to, the Company's ability to satisfy the conditions associated with its cultivation licence, the Company's ability to obtain a sales licence and the related timing considerations, the availability of further financing, consumer interest in its products, competition, regulation, operational and technological risks, and anticipated and unanticipated costs and delays. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents, which can be found under the Company's profile on www.sedar.com.
For more information contact:
Sebastian de Kloet
Phone: 1 (905) 979 - 5173
Email: Sebastian@beleave.com